Fibrin and other physiological Factor XIII transglutaminase substrates (FXIII substrates)

Fibrin and other physiological Factor XIII (FXIII) transglutaminase substrates are a group of proteins essential for the final stages of the coagulation cascade and subsequent wound healing (StatPearls, 2023). Fibrin, the primary substrate, is formed from fibrinogen and undergoes covalent cross-linking by activated Factor XIII (FXIIIa) to create a stable, insoluble meshwork that forms the structural backbone of a blood clot (UniProt P02671). Beyond fibrin, FXIIIa incorporates other substrates such as alpha2-antiplasmin, fibronectin, and collagen into the clot, which enhances its resistance to premature degradation (fibrinolysis) and provides a scaffold for cellular infiltration during tissue repair (PubMed: 28296771). Dysregulation of these substrates or their cross-linking process is linked to various pathologies, including life-threatening bleeding disorders in FXIII deficiency and increased risk of thrombosis or impaired wound healing (NIH, 2022). Therapeutic interventions often focus on replacing FXIII to ensure proper substrate cross-linking or, conversely, targeting fibrin directly with thrombolytic agents to dissolve pathological clots (PubChem).

Other names

FibrinFactor XIIIa substratesTransglutaminase substratesCross-linked fibrinFibrinogen-derived fibrin

Drugs targeting these substrates either facilitate their cross-linking (FXIII replacement therapy) to stabilize clots or catalyze the degradation of the cross-linked fibrin mesh (thrombolytics) to restore blood flow.